Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service tumor & fibroid embolization cases in Tennessee: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 11% on average (118 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 6 | 326 | 43% |
| 2020 | 8 | 310 | 46% |
| 2021 | 7 | 328 |
Chemo- and radioembolization of liver tumors, uterine fibroid and other organ embolization (one code covers all). Professional codes (what the surgeon bills): CPT 37243.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 87% of the cases CMS names in Tennessee; 9 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Breast biopsy & localization | 81 | 4,468−4.7%/yr | −4.7%/yr | 6.81.0× | 31% | 4,740 in 2030+1%/yr |
| Tumor ablation |
Tumor & fibroid embolization in every state, and its device makers · Every procedure market in Tennessee · Every state · Compare with Florida
| ≈ 1,060 |
| – |
| 2026 est. | ≈ 1,170 | – |
| 49% |
| 2022 | 12 | 447 | 52% |
| 2023 | 12 | 435 | 55% |
| 2024 | 13 | 482 | 57% |
| 2025 from claims | – | 1,065 861–1,250 | 57% |
| 2026 forecast | – | 1,166 913–1,464 | 58% |
| 2027 forecast | – | 1,275 946–1,686 | 58% |
| 2028 forecast | – | 1,395 987–1,925 | 58% |
| 2029 forecast | – | 1,525 1,037–2,187 | 59% |
| 2030 forecast | – | 1,668 1,092–2,475 | 59% |
In 2025, 2% inpatient hospital, 27% hospital outpatient, 71% office. The share outside the hospital has moved +67 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Office |
|---|---|---|---|
| 2026 · ~1,200 | ~15 | ~240 | ~910 |
| 2027 · ~1,300 | ~15 | ~220 | ~1,000 |
| 2028 · ~1,400 | ~15 | ~220 | ~1,200 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: office about 83% (71% in 2025), hospital outpatient about 16% (27% in 2025).
| +2.9%/yr |
| 0.6 |
| 63% |
| 3,140 in 2030+17%/yr |
| Virginia | 12 | 902+21%/yr | +21%/yr | 0.9 | 55% | 2,310 in 2030+17%/yr |
| North Carolina | 11 | 795+10%/yr | +10%/yr | 0.8 | 63% | 1,900 in 2030+16%/yr |
| Maryland | 12 | 701+17%/yr | +17%/yr | 0.8 | 80% | 1,270 in 2030+10%/yr |
| Georgia | 5 | 259−8.1%/yr | −8.1%/yr | 0.3 | 64% | 920 in 2030+23%/yr |
| Kentucky | 1 | 248+17%/yr | +17%/yr | 0.5 | 79% | 1,090 in 2030+28%/yr |
| South Carolina | 7 | 207−3.3%/yr | −3.3%/yr | 0.3 | 46% | 820 in 2030+26%/yr |
| Alabama | 5 | 198+0.2%/yr | +0.2%/yr | 0.5 | 68% | 810 in 2030+26%/yr |
| Mississippi | 6 | 194+19%/yr | +19%/yr | 0.5 | 36% | 380 in 2030+12%/yr |
| Oklahoma | 2 | 185+1.4%/yr | +1.4%/yr | 0.4 | 22% | 180 in 2030−0.6%/yr |
| Louisiana | 3 | 167−2.6%/yr | −2.6%/yr | 0.4 | 37% | 260 in 2030+7.6%/yr |
| Arkansas | 3 | 165−1.3%/yr | −1.3%/yr | 0.4 | 73% | 740 in 2030+29%/yr |
| District of Columbia | 3 | 100−4.1%/yr | −4.1%/yr | 1.6 | 87% | 160 in 2030+7.9%/yr |
| 3 |
| 213+0.5%/yr |
| +0.5%/yr |
| 0.31.0× |
| 0% |
| 280 in 2030+4.6%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Exact Sciences leads with 25% of company spending on these surgeons in 2025, +9 pts on 2024.
In 2025, 19 companies reported engagement with Tennessee’s surgeons worth $253K in consulting, speaking, meals and travel tied to these products, about $19K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 16 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.